Oral Povorcitinib for Extensive Nonsegmental Vitiligo Yields Positive Results in Phase 2b Trial

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.

Related Keywords

Paris ,France General ,France ,Khaled Ezzedine ,Kurt Brown ,Povorcitinib Global Program Head At Incyte ,European Academy Of Dermatology ,European Academy ,Total Vitiligo Area Scoring Index ,Vitiligo Area Scoring Index ,Vice President ,Povorcitinib Global Program Head ,Announces Positive ,Week Data ,Study Evaluating Povorcitinib ,Extensive Nonsegmental ,Povorcitinib Significantly Improves Total ,Facial Vitiligo ,Vitiligo ,Povocitinib ,Nonsegmental ,Phase 2b ,Jeeadv ,